Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Sep 16;31(30):3782–3790. doi: 10.1200/JCO.2012.47.4007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by American Society of Clinical Oncology

PMC Copyright notice

Fig A1. — Overall survival stratified by donor KIR2DL1 functional allelic groups. (A) Survival of patients who received a graft from a haploidentical (H), sibling (S), or unrelated (U) donor. (B) Survival of patients who received a T cell depleted (yes) or replete (no) graft. (C) Survival of patients who received a myeloablative (yes) or nonmyeloablative (no) conditioning. CC, KIR2DL1-C²⁴⁵ homozygous graft; P_RR, P_RC, and P_CC, P values when comparing patients who received a similar RR, RC, or CC donor graft, respectively; P×_RR, _RC/CC, P value when comparing the RR and RC groups with the CC group in the corresponding subset; RC, KIR2DL1-R²⁴⁵/C²⁴⁵ heterozygous graft; KIR2DL1-R²⁴⁵ homozygous graft.